Lioresal
Executive Summary
Medtronic's NDA for intrathecal Lioresal (Ciba-Geigy's baclofen) used with the company's Synchromed pump approved by FDA on June 17. However, Medtronic is still awaiting approval of the Synchromed device component for that indication, a spokesperson said. The company says it does not believe it can begin marketing the combination drug/device therapy until FDA responds to its supplemental premarket approval application for Synchromed. The baclofen solution for use in the pump was unanimously recommended for approval in June 1991 by FDA's Peripheral & Central Nervous System Drugs Advisory Committee for treating refractory spasticity caused by multiple sclerosis and spinal cord injuries ("The Pink Sheet" June 24, 1991, p. 9). Intrathecal baclofen has been "approvable" at FDA since Dec. 26.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth